<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5131">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03040141</url>
  </required_header>
  <id_info>
    <org_study_id>VIS410-203</org_study_id>
    <nct_id>NCT03040141</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Intravenous VIS410 in Addition to Oseltamivir (Tamiflu®) Compared With Oseltamivir Alone in Hospitalized Adults With Influenza A Infection Requiring Oxygen Support</brief_title>
  <official_title>Phase 2b, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of Intravenous VIS410 in Addition to Oseltamivir (Tamiflu®) Compared With Oseltamivir Alone in Hospitalized Adults With Influenza A Infection Requiring Oxygen Support</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Visterra, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Visterra, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to compare the efficacy and safety of VIS410 in combination with oseltamivir
      vs oseltamivir alone in severely ill subjects with influenza A infection requiring oxygen
      support.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to compare the efficacy and safety of VIS410 in combination with oseltamivir
      vs oseltamivir alone in severely ill subjects with influenza A infection requiring oxygen
      support. Subjects will be followed for 56 days.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2017</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the effect of 2 dose levels of VIS410 + oseltamivir on the time to normalization of respiratory function compared to oseltamivir alone</measure>
    <time_frame>56 days</time_frame>
    <description>Time to cessation of O2 support resulting in a stable SpO2 &gt; 95% for at least 6 hours on room air, return to baseline respiratory status, or hospital discharge with no need for O2 support, whichever occurs first</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of 2 dose levels of a single intravenous (IV) dose of VIS410 when administered in combination with oseltamivir in hospitalized subjects with influenza A infection</measure>
    <time_frame>56 days</time_frame>
    <description>The proportion of subjects with AEs and SAEs following administration of VIS410</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of 2 dose levels of VIS410 + oseltamivir vs oseltamivir alone on viral titer in upper respiratory samples</measure>
    <time_frame>56 days</time_frame>
    <description>The difference between VIS410 + oseltamivir and oseltamivir alone treatment groups in peak viral load from nasopharyngeal swabs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of 2 dose levels of VIS410 + oseltamivir vs oseltamivir alone on viral titer in upper respiratory samples</measure>
    <time_frame>56 days</time_frame>
    <description>The difference between VIS410 + oseltamivir and oseltamivir alone treatment groups in time to resolution of viral load from nasopharyngeal swabs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of 2 dose levels of VIS410 + oseltamivir vs oseltamivir alone on time to clinical response</measure>
    <time_frame>56 days</time_frame>
    <description>The difference between VIS410 + oseltamivir and oseltamivir alone treatment groups in time to clinical response defined as resolution of at least 4 of 5 vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of 2 dose levels of VIS410 + oseltamivir vs oseltamivir alone on time to cessation of ventilator support</measure>
    <time_frame>56 days</time_frame>
    <description>The difference between VIS410 + oseltamivir and oseltamivir alone treatment groups in total number of days on ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of 2 dose levels of VIS410 + oseltamivir vs oseltamivir alone on time to resumption of normal activities</measure>
    <time_frame>56 days</time_frame>
    <description>The difference between VIS410 + oseltamivir and oseltamivir alone treatment groups in the number of days to resumption of normal activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of 2 dose levels of VIS410 + oseltamivir vs oseltamivir alone on all-cause and attributable 14- and 28- day mortality</measure>
    <time_frame>28 days</time_frame>
    <description>The difference between VIS410 + oseltamivir and oseltamivir alone treatment groups in all-cause and attributable mortality rates at Day 14 and 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of 2 dose levels of VIS410 + oseltamivir vs oseltamivir alone on time to alleviation of signs and symptoms of influenza as assessed by the FluPro Questionnaire at baseline and post-dose</measure>
    <time_frame>56 days</time_frame>
    <description>The difference between VIS410 + oseltamivir and oseltamivir alone treatment groups in the incidence, severity, and duration of signs and symptoms of influenza-like illness as assessed by the FluPRO Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of 2 dose levels of VIS410 + oseltamivir vs oseltamivir alone on the proportion of subjects with new documented bacterial pneumonia/superinfection</measure>
    <time_frame>56 days</time_frame>
    <description>The difference between VIS410 + oseltamivir and oseltamivir alone treatment groups in the percentage of subjects with new bacterial pneumonia/superinfection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of 2 dose levels of VIS410 + oseltamivir vs oseltamivir alone on the proportion of subjects with influenza-related complications</measure>
    <time_frame>56 days</time_frame>
    <description>The difference between VIS410 + oseltamivir and oseltamivir alone treatment groups in the percentage of subjects with influenza-related complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of 2 dose levels of VIS410 + oseltamivir vs oseltamivir alone on the immunogenicity of VIS410</measure>
    <time_frame>56 days</time_frame>
    <description>The difference between VIS410 + oseltamivir and oseltamivir alone treatment groups in the titer of anti-VIS410 antibody positive samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of 2 dose levels of VIS410 + oseltamivir vs oseltamivir alone on the emergence of resistance to VIS410 and oseltamivir</measure>
    <time_frame>56 days</time_frame>
    <description>Genotypic and/or phenotypic assessments to determine the emergence of VIS410 and oseltamivir-resistant viruses</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Influenza A</condition>
  <arm_group>
    <arm_group_label>VIS410 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous infusion of fixed low dose of VIS410 in addition to oseltamivir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VIS410 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous infusion of fixed high dose of VIS410 in addition to oseltamivir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single intravenous infusion of placebo in addition to oseltamivir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose of VIS410 in addition to oseltamivir</intervention_name>
    <description>Single intravenous infusion of fixed low dose of VIS410 in addition to oseltamivir</description>
    <arm_group_label>VIS410 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose of VIS410 in addition to oseltamivir</intervention_name>
    <description>Single intravenous infusion of fixed high dose of VIS410 in addition to oseltamivir</description>
    <arm_group_label>VIS410 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo in addition to oseltamivir</intervention_name>
    <description>Single intravenous infusion of placebo in addition to oseltamivir</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects aged ≥ 18 years.

          -  Test positive for influenza A by rapid antigen test or with another commercially
             available test on an adequate nasopharyngeal specimen in accordance with the
             manufacturer's instructions, or an acceptable local test, including PCR, FIA, or
             ELISA

          -  Onset of influenza symptoms no more than 5 days before VIS410/placebo infusion;
             symptoms may include cough, dyspnea, sore throat, fever, myalgias, headache, nasal
             symptoms (rhinorrhea, congestion), fatigue, diarrhea, anorexia, nausea, and vomiting.

          -  Need for supplemental oxygen of at least 40% (4 L/min) and/or hypoxemia defined as
             SpO2 of less than 90%

          -  Women of childbearing potential must have a negative pregnancy test within 2 days
             prior to VIS410/placebo infusion.

          -  Women should fulfill one of the following criteria:

               -  Post-menopausal; either amenorrhea ≥ 12 months or follicle stimulating hormone &gt;
                  40 mIU/mL as documented in their medical history

               -  Surgically sterile; hysterectomy, bilateral oophorectomy, or tubal ligation

               -  Women of childbearing potential participating in heterosexual sexual relations
                  must be willing to use adequate contraception from screening until 60 days post
                  VIS410/placebo infusion.

          -  Non-vasectomized (or vasectomized less than 6 months prior to dosing) male subjects
             who have a female partner of childbearing potential must use an effective birth
             control method from screening until 60 days post VIS410/placebo infusion.

          -  Subject, or a legally authorized representative (LAR), is able to understand the
             purpose and risks of the study and willing to give voluntary written informed
             consent.

        Exclusion Criteria:

          -  Known or suspected intolerance or hypersensitivity to VIS410, oseltamivir,
             pretreatment medications (diphenhydramine, or to both ibuprofen and acetylsalicylic
             acid [ASA]), or closely related compounds (eg, other monoclonal antibodies)

          -  History of receiving monoclonal antibody products (including VIS410) within 3 months
             prior to VIS410/placebo dosing or planned administration during the study period

          -  Subjects who have taken more than 6 doses of an approved antiviral therapy for
             influenza within the prior 96 hours (eg, oral oseltamivir, inhaled zanamivir, IV
             peramivir, or oral ribavirin) between onset of symptoms and VIS410/placebo dosing

          -  Subjects with lung transplant or history of severe chronic lung disease or any
             condition requiring &gt; 2 L/minute of home oxygen therapy (ie, severe chronic
             obstructive pulmonary disease [COPD], pulmonary fibrosis)

          -  Subjects on extracorporeal membrane oxygenation (ECMO) at time of randomization

          -  Subjects with active graft-vs-host disease, hematopoietic stem cell transplant within
             the previous 90 days, or human immunodeficiency virus infection with a CD4 cell count
             of less than 200 per cubic millimeter

          -  Hospitalization for &gt; 48 hours prior to randomization

          -  High probability of mortality within 48 hours of randomization as determined by the
             Investigator

          -  Subjects weighing less than 45 kg

          -  Enrollment in any other investigational drug or device study, any disease or vaccine
             study within 30 days prior to Day 1 or within 5 half-lives of the investigational
             compound, whichever is longer

          -  Known or suspected alcohol or drug abuse, that is, abuse of a level that would
             compromise the safety or cooperation of the subject in the opinion of the
             Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Visterra</last_name>
    <phone>617-498-1070</phone>
  </overall_contact>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 30, 2017</lastchanged_date>
  <firstreceived_date>January 23, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oseltamivir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
